18 October 2022 | News
Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve therapy selection
Image credit: GE Healthcare
Australia-based Telix Pharmaceutical has announced a collaborative development and reseller agreement with GE Healthcare to supply its investigational positron emission tomography (PET) imaging radiotracers, TLX250-CDx (89Zr-DFO-girentuximab), and [18F]-FLac (18F-3-fluoro-2-hydroxypropionate) for use in third party clinical research and development activities. These novel tracers offer the potential to provide key information about the metabolic environment of tumours, which could help to inform and improve therapy selection.
Under the agreement, GE Healthcare will be responsible for the directed marketing and sales of Telix's imaging agents to pharmaceutical companies, with the close support of Telix, whilst Telix will be responsible for manufacturing and ongoing development of each product.
Telix and GE Healthcare will explore validation of [18F]-FLac for use in GE Healthcare's FASTlab, an automated PET radiochemistry synthesiser, widely used for onsite production of FDG6 and other PET tracers. The agreement has an initial term of five years.
TLX250-CDx - the subject of Telix's recently completed Phase III ZIRCON study in clear cell renal cell carcinoma - targets the antigen, carbonic anhydrase IX (CAIX).
[18F]-FLac, which Telix in-licensed in 2021, has shown promise in imaging lactate metabolism in oxygenated tumours. Understanding tumour lactate metabolic status could guide treatment decisions towards immunotherapy combinations that overcome this barrier.